Johnson & Johnson exceeded analyst expectations in the second quarter, boosting profits thanks to strong Darzalex sales and growth in the medical device sector. The company also revised its year-end sales forecast upwards.
… J&J raised its year-end total sales target to a range of $93.2–$93.6 billion.
Furthermore, with the Trump administration pausing tariffs on China, the expected tariff costs for 2025 were reduced from $400 million to $200 million.
CFO Joseph Wolk emphasized operational strength, stating, “Even in this environment, we increased our profit forecast by 25 cents.”
The adjusted earnings per share forecast for 2025 has been revised down to a range of $10.80–$10.90.
The company’s shares rose 1.1% to $156.90 in pre-market trading.
